logo-loader
viewTissue Regenix Group PLC

Tissue Regenix Group - Resolution of Cyber Security Incident

RNS Number : 9167B
Tissue Regenix Group PLC
04 February 2020
 

This announcement contains inside information

Tissue Regenix Group plc

Resolution of Cyber Security Incident

Leeds, 4 February 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company") the regenerative medical devices company, is pleased to confirm that due to actions taken following the cyber security incident, as originally  reported by the Company on 28 January 2020, the recovery has now been completed and all critical IT systems have been restored and brought back online.  All processing in the Company's United States facility has also resumed with immediate effect.

The incident is projected to have a very short-term impact on the Company's ability to service customer demand, and it is anticipated that delayed orders will be dispatched over the coming weeks. Based on the Company's  initial investigations, there are no indications of any external transfer of sensitive or financial data, and the Company does not expect any associated costs of the system restoration to be material to the short-term cash flow.

The Company has implemented additional data security procedures to reduce the risk of future similar incidents from occurring, and will review its IT security procedures and service providers on an ongoing basis moving forward.    

 

 

The person responsible for this announcement is John Samuel, Executive Chairman.

 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson                                 Head of Communications  

 

Tel: 0330 430 3073

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600

 

 

 

FTI Consulting 

Simon Conway / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCFZGGZMDKGGZM

Quick facts: Tissue Regenix Group PLC

Price: 0.315

Market: AIM
Market Cap: £22.15 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 heads higher as markets welcome easing of restrictions

Headlines from the Proactive UK newsroom. The FTSE 100 rose 21 points to 6,957 as markets welcomed more easing of coronavirus lockdown measures across Europe despite some confusion in the UK. UK prime minister Boris Johnson, though, is being pressed for more clarity on the relaxation of UK...

on 11/5/20